{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:00Z","timestamp":1792788240643,"version":"4.5.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alzheimer\u2019s Association","award":["23AARF-1029815"],"award-info":[{"award-number":["23AARF-1029815"]}],"id":[{"id":"https:\/\/ror.org\/0375f4d26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG078106"],"award-info":[{"award-number":["AG078106"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1RF1 AG058657, 1R01NS136122"],"award-info":[{"award-number":["1RF1 AG058657, 1R01NS136122"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cure Alzheimer\u2019s Fund","id":[{"id":"https:\/\/ror.org\/05ewr7t48","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"DOI":"10.1186\/s13024-026-00965-x","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:36:34Z","timestamp":1782491794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice"],"prefix":"10.1186","volume":"21","author":[{"given":"Praveen","family":"Bathini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Ulrich","family":"Rahfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi C.","family":"Saido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Lemere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"965_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136.","journal-title":"Science"},{"key":"965_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","volume":"6","author":"CA Lemere","year":"2010","unstructured":"Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010;6:108\u201319.","journal-title":"Nat Rev Neurol"},{"key":"965_CR3","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324.","journal-title":"Brain"},{"key":"965_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367\u201385.","journal-title":"Alzheimers Dement"},{"key":"965_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2023","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer\u2019s Disease. BioDrugs. 2023;38:5\u201322.","journal-title":"BioDrugs"},{"key":"965_CR6","doi-asserted-by":"crossref","unstructured":"Jeremic D, Navarro-L\u00f3pez JD, Jim\u00e9nez-D\u00edaz L. Donanemab outperformed Aducanumab and Lecanemab on cognitive, but not on biomarker and safety outcomes: systematic review, frequentist and Bayesian network meta-analyses. 2024 [cited 2024 Sep 30]; Available from: https:\/\/europepmc.org\/article\/PPR\/PPR831437clientbot.","DOI":"10.1101\/2024.03.31.24305134"},{"key":"965_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12883-025-04302-5","volume":"25","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yu Q, Chen B, Zhou J, Li Z, Liao W, et al. Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for Alzheimer\u2019s disease and a literature review. BMC Neurol. 2025;25:281.","journal-title":"BMC Neurol"},{"key":"965_CR8","doi-asserted-by":"publisher","unstructured":"Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, et al. Amyloid-related imaging abnormalities with donanemab in early symptomatic alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized clinical trials. JAMA Neurol [Internet]. 2025; Available from: https:\/\/doi.org\/10.1001\/jamaneurol.2025.0065.","DOI":"10.1001\/jamaneurol.2025.0065"},{"key":"965_CR9","doi-asserted-by":"crossref","unstructured":"Honig LS, Barakos J, Dhadda S, Kanekiyo M, Reyderman L, Irizarry M, et al. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease. Alzheimers Dement: Transl Res Clin Interv. 2023;9:e12377.","DOI":"10.1002\/trc2.12377"},{"key":"965_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"965_CR11","doi-asserted-by":"publisher","unstructured":"Bilodeau PA, Dickson JR, Kozberg MG. The impact of anti-amyloid immunotherapies on stroke care. J Clin Med Res [Internet]. 2024;13. Available from: https:\/\/doi.org\/10.3390\/jcm13051245.","DOI":"10.3390\/jcm13051245"},{"key":"965_CR12","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3174\/ajnr.A7759","volume":"44","author":"M Zedde","year":"2023","unstructured":"Zedde M, Pascarella R, Piazza F. CAA-ri and ARIA: Two Faces of the Same Coin? AJNR Am J Neuroradiol. 2023;44:E13\u20134.","journal-title":"AJNR Am J Neuroradiol"},{"key":"965_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.1440-1789.2000.00268.x","volume":"20","author":"M Yamada","year":"2000","unstructured":"Yamada M. Cerebral amyloid angiopathy: an overview. Neuropathology. 2000;20:8\u201322.","journal-title":"Neuropathology"},{"key":"965_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1749-6632.2000.tb06360.x","volume":"903","author":"JM Olichney","year":"2000","unstructured":"Olichney JM, Hansen LA, Lee JH, Hofstetter CR, Katzman R, Thal LJ. Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer\u2019s disease. Ann N Y Acad Sci. 2000;903:138\u201343.","journal-title":"Ann N Y Acad Sci"},{"key":"965_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnen\/61.3.282","volume":"61","author":"DR Thal","year":"2002","unstructured":"Thal DR, Ghebremedhin E, R\u00fcb U, Yamaguchi H, Del Tredici K, Braak H. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002;61:282\u201393.","journal-title":"J Neuropathol Exp Neurol"},{"key":"965_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11596-019-2007-5","volume":"39","author":"H Nie","year":"2019","unstructured":"Nie H, Hu Y, Liu N, Zhang P, Li G-G, Li Y-Y, et al. Apolipoprotein E Gene Polymorphisms Are Risk Factors for Spontaneous Intracerebral Hemorrhage: A Systematic Review and Meta-analysis. Curr Med Sci. 2019;39:111\u20137.","journal-title":"Curr Med Sci"},{"key":"965_CR17","doi-asserted-by":"publisher","first-page":"e70057","DOI":"10.1002\/alz.70057","volume":"21","author":"C Chu","year":"2025","unstructured":"Chu C, Ma L, Wang Y, Huynh ALH, Dunstan MK, Cui X, et al. Predicting severity of cerebral amyloid angiopathy neuropathology: A modeling approach using NACC and ROSMAP data. Alzheimers Dement. 2025;21:e70057.","journal-title":"Alzheimers Dement"},{"key":"965_CR18","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med [Internet]. 2023 [cited 2025 Apr 17]; Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2212948."},{"key":"965_CR19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.14283\/jpad.2024.159","volume":"11","author":"LBE Shields","year":"2024","unstructured":"Shields LBE, Hust H, Cooley SD, Cooper GE, Hart RN, Dennis BC, et al. Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center. J Prev Alzheimers Dis. 2024;11:1549\u201362.","journal-title":"J Prev Alzheimers Dis"},{"key":"965_CR20","doi-asserted-by":"publisher","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, et al. Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease. Nat Commun. 2023;14:8220.","journal-title":"Nat Commun"},{"key":"965_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, Jamshidi P, Stamm B, Flanagan ME, Sugg E, Tang M, et al. Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke. N Engl J Med. 2023;388:478\u20139.","journal-title":"N Engl J Med"},{"key":"965_CR22","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379.","journal-title":"Science"},{"key":"965_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005;25:629\u201336.","journal-title":"J Neurosci"},{"key":"965_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1742-2094-1-24","volume":"1(1)","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1(1):24.","journal-title":"J Neuroinflammation"},{"key":"965_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities (ARIA) in Alzheimer\u2019s disease patients treated with bapineuzumab: A retrospective analysis. Lancet Neurol. 2012;11:241.","journal-title":"Lancet Neurol"},{"key":"965_CR26","first-page":"e12306","volume":"8","author":"R Aldea","year":"2022","unstructured":"Aldea R, Grimm HP, Gieschke R, Hofmann C, Lott D, Bullain S, et al. In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model. Alzheimers Dement. 2022;8:e12306.","journal-title":"Alzheimers Dement"},{"key":"965_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF02890024","volume":"56","author":"P Eikelenboom","year":"1989","unstructured":"Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer\u2019s dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56:259\u201362.","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"965_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1742-2094-4-22","volume":"4","author":"R Fan","year":"2007","unstructured":"Fan R, DeFilippis K, Van Nostrand WE. Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition. J Neuroinflammation. 2007;4:22.","journal-title":"J Neuroinflammation"},{"key":"965_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-025-00916-y","volume":"21","author":"M-T Papavergi","year":"2025","unstructured":"Papavergi M-T, Bathini P, Singh B, Lemere CA. The complement cascade in Alzheimer\u2019s disease: modern implications of an ancient immune protagonist. Mol Neurodegener. 2025;21:5.","journal-title":"Mol Neurodegener"},{"key":"965_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.4049\/jimmunol.1901068","volume":"204","author":"AJ Tenner","year":"2020","unstructured":"Tenner AJ. Complement-Mediated Events in Alzheimer\u2019s Disease: Mechanisms and Potential Therapeutic Targets. J Immunol. 2020;204:306\u201315.","journal-title":"J Immunol"},{"key":"965_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-020-02024-8","volume":"17","author":"ND Schartz","year":"2020","unstructured":"Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Neuroinflammation. 2020;17:1\u201325.","journal-title":"J Neuroinflammation"},{"key":"965_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000486091","volume":"44","author":"K Matsuo","year":"2017","unstructured":"Matsuo K, Shindo A, Niwa A, Tabei K-I, Akatsu H, Hashizume Y, et al. Complement activation in capillary cerebral amyloid angiopathy. Dement Geriatr Cogn Disord. 2017;44:343\u201353.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"965_CR33","doi-asserted-by":"publisher","unstructured":"Grenon MB, Papavergi M-T, Bathini P, Sadowski M, Lemere CA. Temporal characterization of the amyloidogenic APPswe\/PS1dE9;hAPOE4 mouse model of Alzheimer\u2019s disease. Int J Mol Sci [Internet]. 2024;25. Available from: https:\/\/doi.org\/10.3390\/ijms25115754.","DOI":"10.3390\/ijms25115754"},{"key":"965_CR34","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.molimm.2010.05.007","volume":"47","author":"VP Ferreira","year":"2010","unstructured":"Ferreira VP, Pangburn MK, Cort\u00e9s C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol. 2010;47:2187.","journal-title":"Mol Immunol"},{"key":"965_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581:71.","journal-title":"Nature"},{"key":"965_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00401-011-0801-7","volume":"121","author":"CA Hawkes","year":"2011","unstructured":"Hawkes CA, H\u00e4rtig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, et al. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 2011;121:431\u201343.","journal-title":"Acta Neuropathol"},{"key":"965_CR37","first-page":"1","volume":"16","author":"A Bonaterra-Pastra","year":"2024","unstructured":"Bonaterra-Pastra A, Sol\u00e9 M, Lope-Piedrafita S, Lucas-Parra M, Castellote L, Marazuela P, et al. The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy. Alzheimer\u2019s Res Therapy. 2024;16:1\u201315.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"965_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s13311-020-00839-0","volume":"17","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Di Napoli M, Ricci S, Divani AA. Matrix metalloproteinases in acute intracerebral hemorrhage. Neurotherapeutics. 2020;17:484\u201396.","journal-title":"Neurotherapeutics"},{"key":"965_CR39","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, et al. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer\u2019s Disease Treated with Anti-Amyloid Beta Therapy. J Prev Alzheimers Dis. 2022;9:211\u201320.","journal-title":"J Prev Alzheimers Dis"},{"key":"965_CR40","doi-asserted-by":"publisher","first-page":"1326784","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784.","journal-title":"Front Neurosci"},{"key":"965_CR41","doi-asserted-by":"publisher","first-page":"1412006","DOI":"10.3389\/fnagi.2024.1412006","volume":"16","author":"KE Foley","year":"2024","unstructured":"Foley KE, Wilcock DM. Three major effects of APOE on A\u03b2 immunotherapy induced ARIA. Front Aging Neurosci. 2024;16:1412006.","journal-title":"Front Aging Neurosci"},{"key":"965_CR42","doi-asserted-by":"publisher","first-page":"e3613","DOI":"10.1097\/MD.0000000000003613","volume":"95","author":"C Salvarani","year":"2016","unstructured":"Salvarani C, Morris JM, Giannini C, Brown RD Jr, Christianson T, Hunder GG. Imaging Findings of Cerebral Amyloid Angiopathy, A\u03b2-Related Angiitis (ABRA), and Cerebral Amyloid Angiopathy-Related Inflammation: A Single-Institution 25-Year Experience. Medicine. 2016;95:e3613.","journal-title":"Medicine"},{"key":"965_CR43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1113\/JP275105","volume":"596","author":"ME Pizzo","year":"2017","unstructured":"Pizzo ME, Wolak DJ, Kumar NN, Brunette E, Brunnquell CL, Hannocks M, et al. Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. J Physiol. 2017;596:445.","journal-title":"J Physiol"},{"key":"965_CR44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation DA, Sweeney MD, Montagne A, Sagare AP, D\u2019Orazio LM, Pachicano M, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25:270\u20136.","journal-title":"Nat Med"},{"key":"965_CR45","doi-asserted-by":"publisher","first-page":"105466","DOI":"10.1016\/j.ebiom.2024.105466","volume":"110","author":"H van den Brink","year":"2024","unstructured":"van den Brink H, Voigt S, Kozberg M, van Etten ES. The role of neuroinflammation in cerebral amyloid angiopathy. EBioMedicine. 2024;110:105466.","journal-title":"EBioMedicine"},{"key":"965_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13195-019-0553-5","volume":"11","author":"WJ Meilandt","year":"2019","unstructured":"Meilandt WJ, Maloney JA, Imperio J, Lalehzadeh G, Earr T, Crowell S, et al. Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A\u03b2. Alzheimers Res Ther. 2019;11:97.","journal-title":"Alzheimers Res Ther"},{"key":"965_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-61691-2","volume":"14","author":"L S\u00f6derberg","year":"2024","unstructured":"S\u00f6derberg L, Johannesson M, Gkanatsiou E, Nygren P, Fritz N, Zachrisson O, et al. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Sci Rep. 2024;14:1\u201315.","journal-title":"Sci Rep"},{"key":"965_CR48","doi-asserted-by":"publisher","first-page":"e70086","DOI":"10.1002\/alz.70086","volume":"21","author":"E Fertan","year":"2025","unstructured":"Fertan E, Lam JYL, Albertini G, Dewilde M, Wu Y, Akingbade OES, et al. Lecanemab preferentially binds to smaller aggregates present at early Alzheimer\u2019s disease. Alzheimers Dement. 2025;21:e70086.","journal-title":"Alzheimers Dement"},{"key":"965_CR49","doi-asserted-by":"publisher","unstructured":"Soto-Rojas LO, Campa-C\u00f3rdoba BB, Harrington CR, Salas-Casas A, Hernandes-Alejandro M, Villanueva-Fierro I, et al. Insoluble vascular amyloid deposits trigger disruption of the neurovascular unit in Alzheimer\u2019s disease brains. Int J Mol Sci [Internet]. 2021;22. Available from: https:\/\/doi.org\/10.3390\/ijms22073654.","DOI":"10.3390\/ijms22073654"},{"key":"965_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3988\/jcn.2011.7.1.1","volume":"7","author":"A Biffi","year":"2011","unstructured":"Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol. 2011;7:1\u20139.","journal-title":"J Clin Neurol"},{"key":"965_CR51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40478-021-01303-6","volume":"10","author":"A Zellner","year":"2022","unstructured":"Zellner A, M\u00fcller SA, Lindner B, Beaufort N, Rozemuller AJM, Arzberger T, et al. Proteomic profiling in cerebral amyloid angiopathy reveals an overlap with CADASIL highlighting accumulation of HTRA1 and its substrates. Acta Neuropathol Commun. 2022;10:6.","journal-title":"Acta Neuropathol Commun"},{"key":"965_CR52","doi-asserted-by":"publisher","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","volume":"15","author":"HP Grimm","year":"2023","unstructured":"Grimm HP, Schumacher V, Sch\u00e4fer M, Imhof-Jung S, Freskg\u00e5rd P-O, Brady K, et al. Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. mAbs. 2023;15:2261509.","journal-title":"mAbs"},{"key":"965_CR53","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41591-018-0336-8","volume":"25","author":"C Yin","year":"2019","unstructured":"Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med. 2019;25:496\u2013506.","journal-title":"Nat Med"},{"key":"965_CR54","doi-asserted-by":"publisher","first-page":"e56467","DOI":"10.15252\/embr.202256467","volume":"24","author":"L Chernyaeva","year":"2023","unstructured":"Chernyaeva L, Ratti G, Teiril\u00e4 L, Fudo S, Rankka U, Pelkonen A, et al. Reduced binding of apoE4 to complement factor H promotes amyloid-\u03b2 oligomerization and neuroinflammation. EMBO Rep. 2023;24:e56467.","journal-title":"EMBO Rep"},{"key":"965_CR55","doi-asserted-by":"crossref","unstructured":"Madenspacher JH, Morrell ED, McDonald JG, Thompson BM, Li Y, Birukov KG, et al. 25-Hydroxycholesterol exacerbates vascular leak during acute lung injury. JCI Insight [Internet]. 2023 [cited 2025 May 9];8. Available from: http:\/\/insight.jci.org\/articles\/view\/155448\/files\/pdf.","DOI":"10.1172\/jci.insight.155448"},{"key":"965_CR56","doi-asserted-by":"publisher","first-page":"103342","DOI":"10.1016\/j.redox.2024.103342","volume":"76","author":"J Liu","year":"2024","unstructured":"Liu J, Pang S-Y, Zhou S-Y, He Q-Y, Zhao R-Y, Qu Y, et al. Lipocalin-2 aggravates blood-brain barrier dysfunction after intravenous thrombolysis by promoting endothelial cell ferroptosis via regulating the HMGB1\/Nrf2\/HO-1 pathway. Redox Biol. 2024;76:103342.","journal-title":"Redox Biol"},{"key":"965_CR57","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12929-022-00790-6","volume":"29","author":"C Camilli","year":"2022","unstructured":"Camilli C, Hoeh AE, De Rossi G, Moss SE, Greenwood J. LRG1: an emerging player in disease pathogenesis. J Biomed Sci. 2022;29:6.","journal-title":"J Biomed Sci"},{"key":"965_CR58","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1089\/hum.2018.120","volume":"30","author":"A Stamatikos","year":"2019","unstructured":"Stamatikos A, Dronadula N, Ng P, Palmer D, Knight E, Wacker BK, et al. ABCA1 Overexpression in endothelial cells in vitro enhances ApoAI-mediated cholesterol efflux and decreases inflammation. Hum Gene Ther. 2019;30:236\u201348.","journal-title":"Hum Gene Ther"},{"key":"965_CR59","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1515\/mr-2023-0048","volume":"4","author":"J Li","year":"2024","unstructured":"Li J, Wang K, Starodubtseva MN, Nadyrov E, Kapron CM, Hoh J, et al. Complement factor H in molecular regulation of angiogenesis. Med Rev (Berl). 2024;4:452\u201366.","journal-title":"Med Rev (Berl)"},{"key":"965_CR60","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41591-025-03574-1","volume":"31","author":"L van Olst","year":"2025","unstructured":"van Olst L, Simonton B, Edwards AJ, Forsyth AV, Boles J, Jamshidi P, et al. Microglial mechanisms drive amyloid-\u03b2 clearance in immunized patients with Alzheimer\u2019s disease. Nat Med. 2025;31:1604\u201316.","journal-title":"Nat Med"},{"key":"965_CR61","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1474-4422(25)00313-8","volume":"24","author":"BDC Boon","year":"2025","unstructured":"Boon BDC, Piura YD, Moloney CM, Chalk JL, Lincoln SJ, Rutledge MH, et al. Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer\u2019s disease treated with aducanumab versus untreated: a retrospective case-control study. Lancet Neurol. 2025;24:931\u201344.","journal-title":"Lancet Neurol"},{"key":"965_CR62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2022;79:13\u201321.","journal-title":"JAMA Neurol"},{"key":"965_CR63","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80.","journal-title":"Alzheimers Res Ther"},{"key":"965_CR64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2. J Alzheimers Dis. 2012;28:49\u201369.","journal-title":"J Alzheimers Dis"},{"key":"965_CR65","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","volume":"24","author":"RS Black","year":"2010","unstructured":"Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24:198\u2013203.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"965_CR66","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1161\/01.RES.0000232544.90675.42","volume":"99","author":"J Mocco","year":"2006","unstructured":"Mocco J, Mack WJ, Ducruet AF, Sosunov SA, Sughrue ME, Hassid BG, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res. 2006;99:209\u201317.","journal-title":"Circ Res"},{"key":"965_CR67","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cells14181440","volume":"14","author":"N Akhter","year":"2025","unstructured":"Akhter N, Lambay A, Almotairi R, Hamadi A, Bhatia K, Ahmad S, et al. The complex role of the complement C3a receptor (C3aR) in cerebral injury and recovery following ischemic stroke. Cells. 2025;14:1440.","journal-title":"Cells"},{"key":"965_CR68","doi-asserted-by":"crossref","unstructured":"Mandel-Brehm C, Retallack H, Knudsen GM, Yamana A, Hajj-Ali RA, Calabrese LH, et al. Evidence for alternative complement cascade activation in primary CNS vasculitis [Internet]. Immunology. bioRxiv; 2018. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/329862v1.","DOI":"10.1101\/329862"},{"key":"965_CR69","doi-asserted-by":"crossref","unstructured":"Tenner AJ, Petrisko TJ. Knowing the enemy: strategic targeting of complement to treat Alzheimer disease. Nat Reviews Neurol. 2025;1\u201315.","DOI":"10.1038\/s41582-025-01073-y"},{"key":"965_CR70","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/1381612043453441","volume":"10","author":"J Acosta","year":"2004","unstructured":"Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des. 2004;10:203\u201311.","journal-title":"Curr Pharm Des"},{"key":"965_CR71","doi-asserted-by":"crossref","unstructured":"Ruan C-C, Ge Q, Li Y, Li X-D, Chen D-R, Ji K-D, et al. Complement-mediated macrophage polarization in perivascular adipose tissue contributes to vascular injury in deoxycorticosterone acetate\u2013salt mice. arteriosclerosis, thrombosis, and vascular biology [Internet]. 2015 [cited 2025 May 9]; Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/ATVBAHA.114.304927.","DOI":"10.1161\/ATVBAHA.114.304927"},{"key":"965_CR72","unstructured":"Daha MR. The possible role of membrane complement regulators in vasculitis. Behring Inst Mitt. 1993;184\u201390."},{"key":"965_CR73","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1042\/CS20257865","volume":"139","author":"Y Li","year":"2025","unstructured":"Li Y, Zeng H, Zhong X. Complement C3 in panvascular disease: a central integrator of immune signaling and vascular remodeling. Clin Sci (Lond). 2025;139:1373\u2013403.","journal-title":"Clin Sci (Lond)"},{"key":"965_CR74","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/blood-2013-05-502229","volume":"122","author":"E Asgari","year":"2013","unstructured":"Asgari E, Le Friec G, Yamamoto H, Perucha E, Sacks SS, K\u00f6hl J, et al. C3a modulates IL-1\u03b2 secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. 2013;122:3473\u201381.","journal-title":"Blood"},{"key":"965_CR75","doi-asserted-by":"publisher","unstructured":"Propson NE, Roy ER, Litvinchuk A, K\u00f6hl J, Zheng H. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J Clin Invest [Internet]. 2021;131. Available from: https:\/\/doi.org\/10.1172\/JCI140966.","DOI":"10.1172\/JCI140966"},{"key":"965_CR76","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S1474-4422(07)70055-8","volume":"6","author":"JM Simard","year":"2007","unstructured":"Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007;6:258\u201368.","journal-title":"Lancet Neurol"},{"key":"965_CR77","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1006\/exnr.1999.7273","volume":"161","author":"J Van Beek","year":"2000","unstructured":"Van Beek J, Bernaudin M, Petit E, Gasque P, Nouvelot A, MacKenzie ET, et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol. 2000;161:373\u201382.","journal-title":"Exp Neurol"},{"key":"965_CR78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/abbi.1993.1112","volume":"301","author":"DL Miller","year":"1993","unstructured":"Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer\u2019s disease. Arch Biochem Biophys. 1993;301:41\u201352.","journal-title":"Arch Biochem Biophys"},{"key":"965_CR79","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1523\/JNEUROSCI.2377-07.2008","volume":"28","author":"S Schroeter","year":"2008","unstructured":"Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci. 2008;28:6787\u201393.","journal-title":"J Neurosci"},{"key":"965_CR80","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/brain\/awv313","volume":"139","author":"KR Bales","year":"2016","unstructured":"Bales KR, O\u2019Neill SM, Pozdnyakov N, Pan F, Caouette D, Pi Y, et al. Passive immunotherapy targeting amyloid-\u03b2 reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain. 2016;139:563\u201377.","journal-title":"Brain"},{"key":"965_CR81","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1523\/JNEUROSCI.5426-06.2007","volume":"27","author":"CM Prada","year":"2007","unstructured":"Prada CM, Garcia-Alloza M, Betensky RA, Zhang-Nunes SX, Greenberg SM, Bacskai BJ, et al. Antibody-Mediated Clearance of Amyloid-\u03b2 Peptide from Cerebral Amyloid Angiopathy Revealed by Quantitative In Vivo Imaging. J Neurosci. 2007;27:1973.","journal-title":"J Neurosci"},{"key":"965_CR82","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/ijms25020817","volume":"25","author":"AF Batista","year":"2024","unstructured":"Batista AF, Khan KA, Papavergi M-T, Lemere CA. The Importance of Complement-Mediated Immune Signaling in Alzheimer\u2019s Disease Pathogenesis. Int J Mol Sci. 2024;25:817.","journal-title":"Int J Mol Sci"},{"key":"965_CR83","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/j.1471-4159.2008.05558.x","volume":"106","author":"J Zhou","year":"2008","unstructured":"Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ. Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer\u2019s disease. J Neurochem. 2008;106:2080\u201392.","journal-title":"J Neurochem"},{"key":"965_CR84","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41593-020-0624-8","volume":"23","author":"N Habib","year":"2020","unstructured":"Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, et al. Disease-associated astrocytes in Alzheimer\u2019s disease and aging. Nat Neurosci. 2020;23:701\u20136.","journal-title":"Nat Neurosci"},{"key":"965_CR85","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13024-024-00743-7","volume":"19","author":"K Uekawa","year":"2024","unstructured":"Uekawa K, Hattori Y, Ahn SJ, Seo J, Casey N, Anfray A, et al. Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress. Mol Neurodegener. 2024;19:52.","journal-title":"Mol Neurodegener"},{"key":"965_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-023-00649-w","volume":"18","author":"X Taylor","year":"2023","unstructured":"Taylor X, Clark IM, Fitzgerald GJ, Oluoch H, Hole JT, DeMattos RB, et al. Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer\u2019s disease mice. Mol Neurodegener. 2023;18:1\u201316.","journal-title":"Mol Neurodegener"},{"key":"965_CR87","doi-asserted-by":"crossref","unstructured":"Turner RJ, Sharp FR, Implications, of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke. Front Cell Neurosci [Internet]. 2016 [cited 2024 Oct 3];10. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4777722\/.","DOI":"10.3389\/fncel.2016.00056"},{"key":"965_CR88","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1038\/s41467-023-39693-x","volume":"14","author":"M Hu","year":"2023","unstructured":"Hu M, Li T, Ma X, Liu S, Li C, Huang Z, et al. Macrophage lineage cells-derived migrasomes activate complement-dependent blood-brain barrier damage in cerebral amyloid angiopathy mouse model. Nat Commun. 2023;14:3945.","journal-title":"Nat Commun"},{"key":"965_CR89","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3233\/JAD-220494","volume":"89","author":"S Saito","year":"2022","unstructured":"Saito S, Yamashiro T, Yamauchi M, Yamamoto Y, Noguchi M, Tomita T, et al. Complement 3 Is a Potential Biomarker for Cerebral Amyloid Angiopathy. J Alzheimers Dis. 2022;89:381\u20137.","journal-title":"J Alzheimers Dis"},{"key":"965_CR90","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40478-020-00972-z","volume":"8","author":"L J\u00e4kel","year":"2020","unstructured":"J\u00e4kel L, Kuiperij HB, Gerding LP, Custers EEM, van den Berg E, Jolink WMT, et al. Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage. Acta Neuropathol Commun. 2020;8:99.","journal-title":"Acta Neuropathol Commun"},{"key":"965_CR91","doi-asserted-by":"publisher","first-page":"5620314","DOI":"10.1155\/2017\/5620314","volume":"2017","author":"F Gragnano","year":"2017","unstructured":"Gragnano F, Sperlongano S, Golia E, Natale F, Bianchi R, Crisci M, et al. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm. 2017;2017:5620314.","journal-title":"Mediators Inflamm"},{"key":"965_CR92","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, et al. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron. 2012;76:908\u201320.","journal-title":"Neuron"},{"key":"965_CR93","doi-asserted-by":"publisher","unstructured":"Bathini P, Sun T, Schenk M, Schilling S, McDannold NJ, Lemere CA. Acute effects of focused ultrasound-induced blood-brain barrier opening on Anti-Pyroglu3 abeta antibody delivery and immune responses. Biomolecules [Internet]. 2022;12. Available from: https:\/\/doi.org\/10.3390\/biom12070951.","DOI":"10.3390\/biom12070951"},{"key":"965_CR94","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40478-015-0250-y","volume":"3","author":"F Liao","year":"2015","unstructured":"Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, et al. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol Commun. 2015;3:70.","journal-title":"Acta Neuropathol Commun"},{"key":"965_CR95","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1523\/JNEUROSCI.0829-08.2008","volume":"28","author":"M Maier","year":"2008","unstructured":"Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia\/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333\u201341.","journal-title":"J Neurosci"},{"key":"965_CR96","doi-asserted-by":"publisher","first-page":"100568","DOI":"10.1016\/j.bbih.2022.100568","volume":"28","author":"P Bathini","year":"2023","unstructured":"Bathini P, Dupanloup I, Zenaro E, Terrabuio E, Fischer A, Ballabani E, et al. Systemic inflammation causes microglial dysfunction with a vascular AD phenotype. Brain Behav Immun Health. 2023;28:100568.","journal-title":"Brain Behav Immun Health"},{"key":"965_CR97","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1369\/0022155414546692","volume":"62","author":"S Liu","year":"2014","unstructured":"Liu S, Grigoryan MM, Vasilevko V, Sumbria RK, Paganini-Hill A, Cribbs DH, et al. Comparative analysis of H&E and Prussian blue staining in a mouse model of cerebral microbleeds. J Histochem Cytochem. 2014;62:767\u201373.","journal-title":"J Histochem Cytochem"},{"key":"965_CR98","doi-asserted-by":"publisher","unstructured":"Devraj K, Gu\u00e9rit S, Macas J, Reiss Y. An in vivo blood-brain barrier permeability assay in mice using fluorescently labeled tracers. J Vis Exp [Internet]. 2018; Available from: https:\/\/doi.org\/10.3791\/57038.","DOI":"10.3791\/57038"},{"key":"965_CR99","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12974-019-1495-3","volume":"16","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Zhang F, Yu Z, Guo S, Liu N, Jiang Y, et al. HDAC3 inhibition prevents blood-brain barrier permeability through Nrf2 activation in type 2 diabetes male mice. J Neuroinflammation. 2019;16:103.","journal-title":"J Neuroinflammation"},{"key":"965_CR100","doi-asserted-by":"crossref","unstructured":"Czupalla CJ, Yousef H, Wyss-Coray T, Butcher EC. Collagenase-based single cell isolation of primary murine brain endothelial cells using flow cytometry. bio-protocol [Internet]. 2018 [cited 2024 Aug 19];8. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6326170\/.","DOI":"10.21769\/BioProtoc.3092"},{"key":"965_CR101","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nprot.2017.158","volume":"13","author":"EE Crouch","year":"2018","unstructured":"Crouch EE, Doetsch F. FACS isolation of endothelial cells and pericytes from mouse brain microregions. Nat Protoc. 2018;13:738\u201351.","journal-title":"Nat Protoc"},{"key":"965_CR102","doi-asserted-by":"crossref","unstructured":"Ruck T, Bittner S, Epping L, Herrmann AM, Meuth SG. Isolation of primary murine brain microvascular endothelial cells. J Vis Exp. 2014;93:e52204.","DOI":"10.3791\/52204"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-026-00965-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:27:39Z","timestamp":1789532859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-026-00965-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1186\/s13024-026-00965-x","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Brigham and Women\u2019s Hospital (BWH Protocol: 2016N000396; CAL). All protocols were strictly designed to minimize animal distress and optimize the number of animals required for the study, in accordance with ethical research standards.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"57"}}